RxDoctor Payments Data

Jorge Gonzalez, MD

Cardiovascular Disease · la Jolla, CANPI 1952560476

Payments from drug & device makers

$4,975in general payments, 2019–2025

Across 69 payments — averaging $72.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Eko Health, Inc.$648
  • Novartis$206
  • E.r. Squibb & Sons, L.L.C.$173
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$155
  • AstraZeneca$127
  • plus $560 from 15 others

What the payments were for

  • Speaking & faculty fees$2,50050%
  • Food & beverage$1,82737%
  • Gifts$64813%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,975 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$577,700
Medicare patients
2,451
Services billed
49,826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban183$237,862
EntrestoSacubitril/Valsartan76$98,631
FarxigaDapagliflozin Propanediol77$82,564
JardianceEmpagliflozin52$74,499
XareltoRivaroxaban39$48,858
Repatha SureclickEvolocumab17$16,490
MultaqDronedarone Hcl13$11,447
Ezetimibe284$10,375
VascepaIcosapent Ethyl13$10,019
Rosuvastatin Calcium279$4,843
Metoprolol Succinate298$4,385
Atorvastatin Calcium347$2,978
Losartan Potassium263$2,813
Spironolactone211$1,958
Eplerenone23$1,753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$42$237,862183 claims
NovartisEntresto$206$98,63176 claims
AstraZenecaFarxiga$127$82,56477 claims
Johnson & JohnsonXarelto$62$48,85839 claims
Sanofi-aventis U.S. LLCMultaq$14$11,44713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →